Navigation Links
Phytomedics, Inc. Awarded QTDP Grant from U.S. Department of Health and Human Services
Date:11/9/2010

JAMESBURG, N.J., Nov. 9, 2010 /PRNewswire/ -- Phytomedics, Inc., a transformational healthcare company developing a novel portfolio of drugs and consumer products solely derived from plant sources, announced today that it has been awarded a grant in the amount of $244,000 under the Qualifying Therapeutic Discovery Project (QTDP) Program to advance the development of its lead product PMI-001 for Rheumatoid Arthritis.  PMI-001 is presently in Phase 2b/3 development.

(Logo: http://photos.prnewswire.com/prnh/20101109/NY97954LOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20101109/NY97954LOGO)

Dr. Laurie Smaldone, Phytomedics President & CEO, commented: "We are very appreciative of the recognition and support provided by this award which we believe affirms that PMI-001 has the potential to address the significant unmet medical needs in Rheumatoid Arthritis."

The QTDP grant program provides support for innovative projects that are determined by the U.S. Department of Health and Human Services to have reasonable potential to result in a new therapy, reduce health care costs, or significantly advance the goal of curing cancer.

PMI-001 is a novel, oral, disease-modifying, botanical drug for use in patients with Rheumatoid Arthritis (RA).  Three U.S. based, clinical trials, including a recently published and compelling 6 month Phase 2b/3 study, have demonstrated efficacy in the range of the intravenous biologic therapies, as a stand-alone therapy in reducing signs and symptoms of RA at all American College of Rheumatology (ACR) endpoints with rapid onset of action (as early as 2 weeks), and the ability to halt joint erosions and narrowing (at 6 months), with an acceptable side effect profile.

Combined with the fact that this drug product is delivered as an oral dosage form, and behaves as a steroid-mimetic without corticosteroid side effects, makes PMI-001 a game changing therapeutic opportunity in RA, as well as in the wider autoimmune disease therapeutic category.

About Phytomedics

Phytomedics, Inc. is a transformational healthcare company developing a novel portfolio of drugs and consumer products solely derived from plant sources. Through its proprietary technology platform, the Company has produced a broad pipeline of lead product candidates, several of which are in clinical development. The company's lead candidate, PMI-001, is a novel, oral, disease modifying anti-rheumatic drug currently being developed as a natural pharmaceutical alternative in rheumatoid arthritis therapy.


'/>"/>
SOURCE Phytomedics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Epeius Biotechnologies Awarded Federal Grant Advancing Tumor-Targeted Cancer Therapy
2. Medrium Awarded Electronic Health Record (EHR) Module Certification by Drummond Group
3. NovaSperse(SM) Nanoparticle Innovator, PharmaNova, Inc., Awarded Four Government Grants Toward Development of New Therapeutic Products Under Congressional Qualifying Therapeutic Discovery Project Initiative
4. Parascript Awarded $244,479.25 Affordable Care Act Grant From the U.S. Government
5. WuXi PharmaTech Awarded GLP Certificate from SFDA for Suzhou Toxicology Facility
6. Neuraltus Pharmaceuticals Awarded $733,437 Under the Qualifying Therapeutic Discovery Projects Grant Program (QTDP)
7. Inspiration Biopharmaceuticals Awarded Two Grants Under the Qualifying Therapeutic Discovery Projects Grant Program (QTDP)
8. Pervasis Therapeutics Awarded Four Grants Under the Qualifying Therapeutic Discovery Project
9. NeoGenomics Awarded $374,000 in R&D Grants from the US Government
10. NuView Life Sciences Awarded Grants Under the Patient Protection and Affordable Care Act of 2010
11. ECRI Institute Awarded AHRQ Contract to Establish National Healthcare Horizon Scanning System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... 2017  This report analyzes the worldwide markets for ... Products: Intermediates, Analytical, and Others. The End ... and Agrochemicals. The report provides separate comprehensive analytics for ... Europe , and Rest of World. Annual estimates ... 2022. Also, a six-year historic analysis is provided for ...
(Date:2/24/2017)... Research and Markets has announced the addition of the ... report to their offering. ... The latest research Urinary Incontinence Drugs Price Analysis and ... global Urinary Incontinence market. The research answers the following questions: ... for Urinary Incontinence and their clinical attributes? How are they positioned ...
(Date:2/23/2017)... MINNEAPOLIS , Feb. 23, 2017  Cogentix Medical, ... manufactures and markets innovative proprietary products for the urology ... and fiscal year ended December 31, 2016 before the ... The Company will host a conference call and ... on Thursday, March 9, 2017 at 11:00 a.m. Eastern ...
Breaking Medicine Technology:
(Date:2/24/2017)... Houston, TX (PRWEB) , ... February 24, 2017 ... ... now offering promotions on tooth replacement options at his office, Antoine Dental Center. ... dental implants for $18,499. Some restrictions may apply, but patients can learn more ...
(Date:2/24/2017)... ... February 24, 2017 , ... An in-depth computational analysis of genetic variants implicated ... to eight genes that may explain why susceptibility to one of the disorders could ... study published today in the journal npj Schizophrenia. , “There is a wealth ...
(Date:2/24/2017)... New York, NY (PRWEB) , ... February 24, 2017 , ... ... urges: “Security needs to be a top priority because it’s not if you will ... in online safety, especially when it comes to digital health care. , Improvements in ...
(Date:2/24/2017)... ... February 24, 2017 , ... The narrative in “ Signal 8: ... ’s true account of his paramedic experiences. Schanssema describes the tragedies he saw, as ... attempts to overcome them. , Schanssema, initially unsure of the career path he wanted ...
(Date:2/24/2017)... ... February 24, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at ... concerning this present generation. Yisrayl makes an astounding statement when he says that ... explains that the Bible details the current times so plainly that anyone should be ...
Breaking Medicine News(10 mins):